Miguel Lopez-Toledano, PhD

  • 2Articles
  • 25.3KReads
  • 2024–2025Active
  • 10Collaborators
  • 5Citations

About

Miguel Lopez-Toledano, PhD, is affiliated with Clinical Development and Medical Affairs at Neurelis Inc in San Diego, California. His publications focus on bipolar disorder, schizophrenia and schizoaffective disorders, and complementary and alternative medicine. He has contributed to research on the pharmacokinetics of olanzapine formulations and alternative approaches for managing acute agitation in psychiatric conditions. His work has appeared in Psychiatrist.com between 2024 and 2025.

Publications

JCP
Pharmacokinetics of Olanzapine Intranasal Spray vs Olanzapine IM
Original Research

Pharmacokinetics of Olanzapine Intranasal Spray vs Olanzapine IM

March 19, 2025

Two investigational intranasal formulations of olanzapine containing the permeation enhancer dodecyl maltoside showed favorable pharmacokinetics and an acceptable safety profile in healthy adults.
, , , et al
PCC
Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder
Narrative Review

Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder

January 30, 2024

While oral and intramuscular formulations of pharmacologic agents continue to be commonly used to treat acute agitation, novel agents with alternative routes of delivery are becoming available.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe